Previous Article | Next Article ![]()
Journal of Virology, December 2000, p. 11027-11039, Vol. 74, No. 23
Howard Hughes Medical
Institute,1 Department of Biochemistry
and Molecular Biophysics,2 Integrated
Program in Cellular, Molecular and Biophysical
Studies,3 and Department of
Microbiology,4 College of Physicians and
Surgeons, Columbia University, New York, New York 10032
Received 10 July 2000/Accepted 12 September 2000
A yeast two-hybrid screen for cellular proteins that interact with
the murine leukemia virus (MuLV) Gag protein resulted in the
identification of nucleolin, a host protein known to function in
ribosome assembly. The interacting fusions contained the
carboxy-terminal 212 amino acids of nucleolin [Nuc(212)]. The
nucleocapsid (NC) portion of Gag was necessary and sufficient to
mediate the binding to Nuc(212). The interaction of Gag with Nuc(212)
could be demonstrated in vitro and was manifested in vivo by the
NC-dependent incorporation of Nuc(212) inside MuLV virions.
Overexpression of Nuc(212), but not full-length nucleolin, potently and
specifically blocked MuLV virion assembly and/or release. A mutant of
MuLV, selected to specifically disrupt the binding to Nuc(212), was
found to be severely defective for virion assembly. This mutant harbors
a single point mutation in capsid (CA) adjacent to the CA-NC junction, suggesting a role for this region in Moloney MuLV assembly. These experiments demonstrate that selection for proteins that bind assembly
domain(s) can yield potent inhibitors of virion assembly. These
experiments also raise the possibility that a nucleolin-Gag interaction
may be involved in virion assembly.
The retroviral gag gene
products play crucial roles at late stages in the viral life cycle,
mediating virion assembly and RNA packaging (reviewed in references
65 and 72). The gag gene of the type C retroviruses is expressed as a precursor protein that moves to the plasma membrane, assembles into large structures, and
induces the formation and release of virion particles. gag mutations have often been found to block virion assembly (1, 33,
61), and expression of the gag gene alone in mammalian cells is sufficient to direct the formation and release of "bald particles" from the cell (19, 63). Thus, the Gag precursor is both necessary and sufficient for assembly, earning the protein the
name "particle making machine" (21). In addition, Gag is important early in infection, during virus entry; many mutations in the
gag gene have no effect on assembly but rather block early stages of infection (3, 17, 31, 73). These studies indicate that some of the Gag domains are actively involved in the process of
uncoating, reverse transcription, and perhaps nuclear transport and entry.
During and after the assembly process, the Gag protein of Moloney
murine leukemia virus (Mo-MuLV) is cleaved by the viral protease into
four products found in the mature virion: matrix (MA), p12, capsid
(CA), and nucleocapsid (NC). The MA domain is required for membrane
targeting of Gag and for virion assembly (57). The p12
protein includes an L domain that is required for late stages of viral
assembly and efficient release from the cell (74). In
addition, some mutations in p12 block early events (17, 75).
The CA domain of Mo-MuLV is important for virion assembly, as most
deletions and many point mutations in CA block this process. A few
point mutations do not affect assembly but rather block the early
stages of infection (3, 37). The NC domain is a highly basic
sequence containing a single Cys-His box, a conserved zinc-binding
motif (CX2CXnHX4C) found in most Gag proteins. Although NC is not absolutely required for assembly, it contains a sequence, termed the I (interaction) domain (65), that is important for multimerization of Gag, and
deletion of NC results in a drastic reduction in particle production.
Point mutations in NC often affect the process of encapsidation of the viral RNA (32, 48, 56), and very subtle mutations, in which Cys and His residues in the Cys-His box are changed to His or Cys,
result in defects in reverse transcription of the RNA or the stability
of the resulting DNA (31).
The complex and diverse activities of the Gag protein raise the
possibility that cellular factors are involved in regulating Gag
functions. Indeed, several cellular gene products have been suggested
to serve as negative or positive factors for Gag activities during the
retrovirus life cycle. Cyclophilin A, a prolyl isomerase thought to be
involved in protein folding, is an example of a cellular factor that
interacts with human immunodeficiency virus type 1 (HIV-1) Gag and
serves as a positive factor for virus replication (44).
Cyclophilin A is incorporated at substantial levels into the HIV-1
virion particle, and this incorporation enhances virus infectivity
(25). A number of other Gag-interacting proteins have
recently been identified. These include H03, a putative histidyl-tRNA synthetase that binds to MA of HIV-1 (41); KIF4, a
microtubule-associated motor protein in the kinesin superfamily that
interacts with different retroviral Gag proteins, including that of
Mo-MuLV and HIV-1 (40, 67); actin and other cytoskeletal
proteins (ezrin, moesin, and cofilin) found in HIV-1 virions
(50); and translation elongation factor 1 To identify new host proteins that bind to Gag, we have applied the
yeast two-hybrid system to screen a mouse cDNA expression library for
proteins that interact with an MuLV Gag polyprotein serving as the
bait. One protein recovered repeatedly was identified as a fragment of
nucleolin, a host protein known to shuttle between the nucleus and the
cytoplasm and to function in ribosome biogenesis. Here we describe the
interaction of MuLV Gag with the C-terminal portion of nucleolin.
We find that this interaction can potently inhibit virus
assembly. Furthermore, a single point mutation adjacent to the
CA-NC boundary, selected to abolish this interaction, also profoundly diminished assembly. Thus, these experiments indicate that
the region of Gag that contains the CA-NC junction is important for
Mo-MuLV assembly and that this region can serve as a target for
inhibiting assembly. These data also raise the possibility that
nucleolin may play a role in this process.
Yeast plasmids.
The yeast expression vector pGADNOT encodes
the C-terminal Gal4 activation domain (Gal4AD) and carries the
LEU2 marker (44); plasmids pSH2-1 (35)
and pBTM116 (6) encode the N-terminal LexA DNA-binding
domain (LexADB) and carry HIS3 and TRP1 markers, respectively; plasmids pMA424 (45) and pAS1 (23),
generously provided by S. Elledge, Baylor College of Medicine, encode
the N-terminal Gal4 DNA-binding domain (Gal4DB), with HIS3
and TRP1 markers, respectively. Plasmids containing the Gag
sequences of HIV-1, simian immunodeficiency virus type 1 (SIV-1),
Mason-Pfizer monkey virus (MPMV), Mo-MuLV, N- and B-tropic MuLVs, and
Rous sarcoma virus (RSV) were as described previously (4, 42, 44). The NC domain of the Mo-MuLV Gag was removed by partial digestion with MscI plus SalI, and the deleted
DNA was transferred into pSH2-1 to generate a LexA-gag Yeast strains.
Saccharomyces cerevisiae strains
GGY::171 and CTY10-5d (39) were generously
provided by R. Sternglanz. BY3171 is the MaV103 reverse two-hybrid
S. cerevisiae strain (70), generously provided by
E. Harlow (Massachusetts General Hospital).
Yeast two-hybrid library construction and screening.
Mouse
cDNAs were obtained from a lambda phage library of cDNAs derived from
the murine cell line WEHI-3 (a BALB/c macrophage/monocyte-derived cell
line) in the directional UNI-ZAP vector (Stratagene). Roughly 106 plaques were pooled, the phage were propagated in
liquid culture, and DNA was prepared by standard procedures
(59). Inserts were excised by cleavage of NotI
and XhoI (resulting in a short polylinker attached to the 5'
end of the cDNAs) and separated by electrophoresis on a 1% agarose
gel. DNA inserts in the range of 0.5 to 4 kb were isolated and ligated
into the NotI and SalI sites in the yeast vector
pGADNOT, and the products were used to transform bacteria. A total of
seven pools of at least 105 colonies were generated and
used to prepare large amounts of plasmid DNA. More than 98% of the
DNAs contained inserts. Since this library is directional, one clone in
three should be in frame with the Gal4AD, and all should be the correct orientation.
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
The Carboxy-Terminal Fragment of Nucleolin Interacts with the
Nucleocapsid Domain of Retroviral Gag Proteins and Inhibits
Virion Assembly
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
, bound to MA
and NC domains of HIV-1 Gag (14). Proteins may also interact
with Gag protein early in infection; one example is the Fv-1 gene
product, which blocks virus infection through effects on the CA domain
(7, 20, 30, 51). It is likely that many other cellular
proteins interact with Gag and are also involved in Gag functions.
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
NC fusion. The
CA-NC and NC domains of Mo-MuLV were amplified by PCR (Expand High
Fidelity PCR system [Boehringer Mannheim]) according to the
manufacturer's protocol, using oligonucleotides
5'TCGCAGGGATCCCCCTCCGCGCAGGA3' and
5'GCGGGATCCGAGCCACTGTCGTTAGTGG3', respectively,
together with oligonucleotide
5'CGCGCGGTCGACAGGAGGGAGG3' (nonviral sequences
are in boldface) from plasmid pNCA (16). The amplified fragments were digested with BamHI and SalI and
cloned into the same sites in pSH2-1. The resulting plasmids,
pSH2-1-CANC and pSH2-1-NC, encode an N-terminal LexADB fused in frame
to the CA-NC and NC domains, respectively. A construct expressing
LexADB fused to lamin (39) was generously provided by R. Sternglanz (Stony Brook, N.Y.). Plasmid pGADNOT-Nuc(212) was isolated
from the yeast two-hybrid screen and harbors a cDNA encoding the last
212 amino acids of the cellular protein nucleolin [Nuc(212)]. A
construct expressing LexADB fused to Nuc(212) was made by transferring
an EcoRI-BglII fragment from pGADNOT-Nuc(212)
(EcoRI and BglII sites are located at a short
polylinker at the 5' end of the cDNA and at the plasmid backbone,
respectively) to plasmid vector pBTM116, creating pBTM-Nuc(212).
-galactosidase (
-Gal) activity as described elsewhere
(44). Blue transformants were restreaked and retested, and
DNA was recovered from positive clones. The DNA was used to transform
Escherichia coli strain Leu
BAI, and
Leu+ transformants were selected to allow recovery of the
cDNA-containing plasmid pGADNOT. These plasmids were then retested in
yeast for activation of
-Gal to confirm their ability to activate in
concert with plasmid pLexADB-Ngag. The sequence of each insert in these plasmids was determined and compared with entries in the GenBank database.
Reverse two-hybrid system.
A
BamHI-SalI fragment, containing the Mo-MuLV CA
and NC sequences from plasmid pSH2-1-CANC, was cloned into the same
sites in the yeast expression vector pAS-1. The resulting plasmid,
pAS1-CANC, encodes a Gal4DB-CA-NC fusion. This plasmid was randomly
mutated using an E. coli mutator strain (XL-1 Red;
Stratagene) according to the manufacturer's protocol, and the library
of mutagenized DNA was used to transform E. coli strain
ElectroMAX DH10B (GIBCO-BRL) to yield about 5 × 106
independent colonies. To obtain a rough estimate of the mutagenesis efficiency of the XL-1 Red strain, a parallel random mutagenesis procedure was performed on plasmid pUC18, and the mutated plasmid library was isolated and used to transform E. coli DH5
.
Colony staining for
-Gal activity revealed that about 1% of the
colonies were white.
His
Leu
KC8 bacteria (Clontech). The pAS1-CANC plasmids recovered were used to
transform yeast strain BY3171 harboring plasmid pGADNOT-Nuc(212) and
were confirmed not to activate the reporter. Restriction digestion of
these plasmids revealed that one was a rearranged plasmid lacking the
insert. DNA sequence analysis of the other two plasmids showed that
only one was mutated in the CA-NC sequence. This mutation (L477P)
changed a leucine codon (CTA) at position 477 of Gag to a proline codon (CCA).
To confirm that no other mutations in the backbone of the plasmid
contributed to the lack of interaction with the Gal4AD-Nuc(212) fusion
protein, the CA-NC sequence was excised by BamHI and
SalI digestion and then cloned into the same sites in
plasmid pGADNOT. The resulting plasmid, pGADNOT-L477P, was
transformed together with pBTM-Nuc(212) into yeast strain CTY10-5d, and
Leu+ Trp+ colonies were selected. No activation
of the lacZ gene was observed in these colonies, indicating
that the L477P mutation is sufficient to disrupt the CA-NC-Nuc(212)
interaction. In addition, these experiments demonstrated that L477P
disrupts this interaction whether the CA-NC sequence is fused to Gal4DB
or to Gal4AD.
In vitro binding experiments.
The Nuc(212) cDNA insert was
excised from plasmid pGADNOT-Nuc(212) by cleavage at an XbaI
site (located at a short polylinker at the 5' end of the cDNA) and a
BglII site (located at the pGADNOT plasmid backbone). This
insert was cloned into the same sites in plasmid pGEX2TKPL, a
derivative of pGEX-2TK (Pharmacia), to form a glutathione
S-transferase (GST)-Nuc(212) fusion. Cultures of E. coli DH5
(200 ml) harboring pGEXT2TKPL or pGEXT2TKPL-Nuc(212) were grown to an optical density at 600 nm of 0.5, induced by the
addition of isopropyl-
-D-thiogalactoside (IPTG) to a
final concentration of 1 mM, and incubated at 37°C for 2 h. The
bacteria were chilled on ice, washed twice with TNEN (50 mM Tris-HCl
[pH 7.5], 0.5% Nonidet P-40 [NP-40], 10 mM EDTA, 50 mM NaCl), and 25% of the bacterial pellet was resuspended in 1 ml of TNENI solution (TNEN solution mixed with 2 mM phenylmethylsulfonyl fluoride (PMSF), aprotinin [1 µg/ml], leupeptin [1 µg/ml], and pepstatin A [1
µg/ml]). The bacteria were disrupted by sonication, and the cell
debris was removed by centrifugation. Extracts of mammalian cells
containing Gag proteins were prepared by lysing Mo-MuLV-infected NIH
3T3 cells with ice-cold TNENI (1 ml per 100-mm-diameter dish); the lysates were passed through a 19-gauge needle and clarified by centrifugation. A 500-µl aliquot of each bacterial lysate was mixed
with 500 µl of the mammalian cell extract. After 1 h of rotation
at 4°C, a slurry of glutathione-agarose beads (20 µl; Sigma) was
added, and incubation was continued for 1 h at 4°C. The beads
were then washed four times with TNENI solution and boiled in 60 µl
of 2× loading buffer (125 mM Tris-HCl [pH 6.8], 2.5% sodium dodecyl
sulfate [SDS], 20% glycerol, 50 µl of
-mercaptoethanol/ml); 20 µl of this mixture was analyzed by Western blotting. In typical experiments, the bound protein obtained from 15 to 20% of the original
lysate was loaded per lane; to allow comparison with the input protein,
2% of the original 1-ml lysate was loaded directly in a parallel lane.
Mammalian expression plasmids. Plasmid pNLENV-1 (46), which lacks the simian virus 40 (SV40) origin of replication, was used to express HIV-1 gag and pol genes (NL4-3 strain). pHIV-HSA, which contains the SV40 origin of replication, carries the HIV-1 genome (HXB2 strain) with a portion of its envelope gene substituted by the mouse heat-stable antigen gene (58) (generously provided by Manfred Schubert, National Institutes of Health, Bethesda, Md.).
Plasmid pXM-MoZipWT expresses a modified Mo-MuLV Gag in which the BZip domain from human CREB (77) was fused to the capsid C terminus, replacing the NC domain (E. Barklis, personal communication). The plasmid was generously provided by E. Barklis (Oregon Health Sciences University). Mo-MuLV was expressed from plasmid pNCA (16) or from pNCS, a derivative carrying an SV40 origin of replication in the plasmid backbone. To introduce the L477P mutation into the Mo-MuLV provirus, an XhoI-SalI fragment was excised from pNCS and from pGADNOT-L477P and cloned into the same sites in pBluescript KS (Stratagene) to create pBLS-wt and pBLS-L477P, respectively. An internal XhoI-NruI fragment (560 bp) was excised from pBLS-wt and replaced with the corresponding fragment derived from pBLS-L477P, to create pBLS-wt-L477P. The mutated gag sequence was then exchanged for the wild-type gag sequence in pNCS, using the XhoI-SalI sites, to form pNCS-L477P. The L477P change abolished an AluI site, which was used to confirm the presence of this mutation. To construct a protease-defective Mo-MuLV, the protease sequence in plasmid pBLS-wt was mutated by using the GeneEditor in vitro site-directed mutagenesis system (Promega) as instructed by the manufacturer along with the oligonucleotide 5'CGTCACCTTCCTGGTCGCGACTGGGGCCCAACAC3' (bold letters represent changes from the wild-type sequence); the mutation results in replacement of the aspartic acid in the protease catalytic site with alanine. The existence of this mutation was verified by the presence of a new NruI site and by additional DNA sequence analysis. The mutated protease sequence was then exchanged for the wild-type sequence in pNCS, using the XhoI-SalI sites, to form plasmid pNCS-Prot
.
To create a Mo-MuLV with a deletion in the RT, a
BclI-BlpI fragment was deleted from pNCA; the
termini were blunted with the Klenow fragment of DNA polymerase I and
ligated. An XhoI-SacII fragment harboring the
deletion was then exchanged for the wild-type sequence in pNCS, using
the same sites, to create pNCS
RT.
A construct expressing hemagglutinin (HA)-tagged cyclophilin A was
generously provided by J. Luban (Columbia University).
A C-terminally Myc-tagged, full-length nucleolin was constructed as
follows. Total RNA extracted from WEHI cells was subjected to reverse
transcription using oligo(dT) as a primer and SuperScript RNase
H
RT (GIBCO-BRL) according to the manufacturer's
protocol. The open reading frame of nucleolin (8) was
amplified from the WEHI cDNA by PCR (Expand High Fidelity PCR system)
as instructed by the manufacturer, using the oligonucleotides
5'CGGAATTCCGGCGCCGTAATCCGCCACC3' and
5'TCCGCCCGGGCATTCAAACTTCGTCTTCTTTCC3'
(nucleotides that flank the nucleolin sequence are in boldface).
The resulting amplified fragment contains an EcoRI site, 20 nucleotides of the 5' untranslated region just upstream of the
nucleolin start codon, and the nucleolin open reading frame with an
SrfI site fused at its 3' (lacking the stop codon). This
fragment was cloned into the SmaI site in plasmid pUC18,
using a SureClone ligation kit (Pharmacia) as instructed by the
manufacturer, creating pUC18-1b. The EcoRI-SrfI
fragment was excised from plasmid pUC18-1b and cloned into the same
sites in pMT21myc (22), creating a full-length open reading
frame of the mouse nucleolin cDNA, fused at its 3' end in frame to the
Myc epitope. N-terminally HA-tagged Nuc(212) was expressed from plasmid
pCGN-Nuc(212), which was constructed by excision of the Nuc(212) cDNA
insert from pGADNOT-Nuc(212), using XbaI and
BglII sites (located at a short polylinker at the 5' end of
the cDNA and at the pGADNOT plasmid backbone, respectively), and was
cloned into the XbaI and BamHI sites of the
mammalian expression vector pCGN (66). An N-terminally
HA-tagged, full-length nucleolin was constructed as follows. The
full-length open reading frame of nucleolin was amplified from plasmid
pUC18-1b by PCR, using the oligonucleotides
5'GGACCTTCTAGAATGGTGAAGCTCGCAAAGGCTGGC3' and
5'CGGCGGAGATCTCTATTCAAACTTCGTCTTCTTTCC3'
(nucleotides that flank the nucleolin sequence are in boldface).
The amplified PCR fragment was digested with XbaI and
BamHI (an internal BamHI site exists in the
C-terminal portion of the nucleolin sequence) and cloned into the same
sites in pCGN-Nuc(212), to generate pCGN-Nucleolin. This plasmid
encodes the full-length nucleolin cDNA fused at its amino terminus in
frame to the HA epitope. Both HA-tagged and Myc-tagged full-length
nucleolin migrated with the same apparent size as the endogenous
nucleolin when extracts of cells expressing these proteins were
analyzed by Western blotting using a monoclonal antibody against the N
terminus of wild-type nucleolin (data not shown).
Transformation of 293T and COS-7 cells. 293T cells were transfected using calcium phosphate (52). Subconfluent COS-7 cells were transfected using DEAE-dextran (55). Expression was analyzed 2 days after transfection for both 293T and COS-7 cells.
RT assay. Exogenous RT assay mixtures (68) were incubated for various times, and the radioactivity of the DNA product was quantitated by PhosphorImager analysis (26). Relative RT activity was calculated from the slope of the graph of radioactivity in DNA (in arbitrary pixel units), plotted against the reaction time (in minutes).
Equilibration centrifugation of virion particles. Virions were purified on 25%/45% sucrose step gradients (62). Virions were also analyzed on 20 to 60% continuous sucrose gradients by centrifugation for 16 h at 80,000 × g at 4°C. Gradient fractions of 0.5 ml were collected; proteins were precipitated with trichloroacetic acid in the presence of 1 µg of bovine serum albumin, resuspended, and analyzed by SDS-gel electrophoresis and Western blotting.
Subtilisin digestion of virions. COS-7 cells (3×100-mm plates) were transfected with 5 µg of pNCS expressing Mo-MuLV, together with 5 µg of plasmid expressing HA-Nuc(212). Two days later the virions were purified from culture supernatants by sucrose step gradients, and virion pellets were resuspended in subtilisin buffer (40 mM Tris [pH 8], 2 mM CaCl2). Various amounts of subtilisin (Boehringer Mannheim D-68298) were added; after incubation at room temperature, reactions were stopped by adding PMSF and aprotinin to final concentrations of 2 mM and 1 µg/ml, respectively. Particles were purified through a 25% sucrose cushion, and the pellets were resuspended and boiled in 2× loading buffer. For subtilisin treatment in the presence of detergent, NP-40 was added to a final concentration of 0.2%; after the reactions were stopped, the mixture was supplemented with an equal volume of 2× loading buffer and boiled.
Western blot analysis and antibodies. Western blot analyses were performed using 10 to 12% polyacrylamide gels and Immobilon-P transfer membrane (Millipore) according to the manufacturer's protocol. Peroxidase-conjugated secondary antibodies were detected by staining the membrane with ECL Western blotting detection reagent (Amersham Pharmacia Biotech) according to the manufacturer's protocol. Goat polyclonal anti-Gag antiserum, raised against Rauscher MuLV, was obtained from the National Cancer Institute (product no. 79S-804). This antiserum cross-reacts with Mo-MuLV Gag and was used at a 1:5,000 dilution. Monoclonal anti-p15E envelope antibody, in culture supernatants of hybridoma line 42-114 (53), was diluted 1:2 before use. Mouse monoclonal antibody against HIV-1 capsid (HIV-018-48171) was purchased from Capricorn, Scarborough, Maine, and used at a 1:5,000 dilution. Mouse monoclonal antibody against the HA epitope (Boehringer Mannheim) was used at a final concentration of 0.4 µg/ml. Peroxidase-conjugated polyclonal antisera raised against goat immunoglobulin G (Boehringer Mannheim) and mouse immunoglobulin G (Amersham Life Sciences) were used at 1:10,000 and 1:3,000 dilutions, respectively.
Transformation of Phoenix cells and assays for transduction. 293T-based, amphotropic or ecotropic Phoenix helper cell lines (34) (generously provided by G. Nolan, Stanford University) were transfected with 2 µg of a Mo-MuLV-based, green fluorescent protein (GFP)-containing retroviral vector (MFG-GFP; generously provided by G. Nolan) and the indicated plasmid DNAs, using the calcium phosphate method (52). The next day the supernatants were replaced with 3 ml of fresh medium. Two days after transfection, the cells were analyzed by fluorescence-activated cell sorting (FACS) for GFP fluorescence. Mock-transfected cells were used to determine the background autofluorescence level of GFP-negative cells. Total fluorescence of the GFP-positive cell population was calculated by multiplying the percentage of GFP-positive cells with their mean fluorescence value. Supernatants of transfected cells were filtered through a 0.45-µm-pore-size filter (GelmanSciences) and diluted 1:3 with culture medium; then Polybrene was added to a final concentration of 5 µg/µl. These virus preparations (2 ml) were used to infect NIH 3T3 cells (2 × 105 cells in 60-mm-diameter dishes) for 2 h. Two days later, fluorescence of the infected, GFP-positive cells was measured by FACS and total fluorescence was calculated. Normalized infectivity was calculated by dividing the total fluorescence of infected cells by the total fluorescence of transfected cells. FACS analysis of GFP-positive cells revealed that between 15 and 45% of the transfected Phoenix cells were transfected and that between 0.1 and 55% of the NIH 3T3 cells were infected.
| |
RESULTS |
|---|
|
|
|---|
Yeast two-hybrid screen for MuLV Gag-interacting proteins. To screen for cellular proteins that interact with the MuLV Gag protein, the LexADB-Ngag fusion protein was used as a bait to screen a mouse cDNA library of sequences expressed as fusions to the Gal4AD. Out of approximately 106 yeast colonies screened, we identified 12 plasmids that reproducibly activated the lacZ reporter gene in the presence of LexADB-Ngag. Three of these clones were independent isolates of the same cDNA, approximately 1.3 kb long, showing complete identity to mouse nucleolin (8). In these clones the Gal4AD sequence was fused in frame to the last 212 amino acids of nucleolin [Nuc(212)]. Nucleolin is a ubiquitous, abundant 100-kDa phosphoprotein with a complex structure and diverse activities (for a recent review, see reference 29). The carboxy two-thirds of nucleolin consists of four RNA-binding domains, also called RNA recognition motifs (RRM) (8-10, 18), followed by a fifth distinct domain, rich in glycine, dimethylarginine, and phenylalanine, called a glycine-arginine-rich (GAR) domain (36, 43). The GAR domain also binds RNA (28, 36, 49) and possesses a nucleic acid helicase activity (27, 69). The region recovered in the yeast plasmid contains a partial copy of the third RRM, a complete copy of the fourth RRM, and the complete GAR helicase region. Three other clones recovered in the screen had no similarity to nucleolin but showed similarity to the DEAD box family of RNA helicases; the corresponding gene was named GIP2.
Gag-Nuc(212) interactions in the yeast two-hybrid system.
To
evaluate the range of Gag proteins that interact with Nuc(212), various
pairs of plasmids encoding different fusion proteins were tested in the
yeast two-hybrid system (Table 1). Gag
proteins of Mo-MuLV and of N- and B-tropic viruses fused to LexADB
(LexADB-Mgag, -Ngag, and -Bgag, respectively) all interacted strongly
with Gal4AD-Nuc(212). Gag proteins from RSV and SIV fused to
Gal4DB (Gal4DB-RSVgag and SIVgag, respectively) also interacted
strongly with Gal4AD-Nuc(212). However, the Gag protein of
HIV-1 fused to Gal4DB (Gal4DB-HIV) showed only weak interaction,
and the Gag protein of MPMV fused to Gal4DB (Gal4DB-MPMV) did not
detectably interact. All of these Gag constructs did not interact with
Gal4AD alone, and Gal4AD-Nuc(212) did not interact with an
irrelevant protein (lamin) fused to LexADB, with LexADB
alone, or with Gal4DB alone. These results indicate that a specific
interaction occurs between Nuc(212) and many, though not all, Gag
proteins in the yeast two-hybrid system.
|
NC), did not interact with Gal4AD-Nuc(212),
indicating that the NC domain was required. A fusion containing the CA
and NC domains, LexADB-CANC, interacted as strongly as the complete Gag protein. LexADB fused to NC alone (LexADB-NC) did interact, though this interaction was somewhat weaker than the interaction with
LexADB-CANC. These data suggest that the NC domain is necessary and
sufficient for the interaction of Nuc(212) and that addition of the CA
domain to the NC domain may stabilize or enhance this interaction.
Nuc(212) binds Mo-MuLV Gag in vitro.
To verify the results
from the yeast two-hybrid system, we tested for the ability of Nuc(212)
to bind to Mo-MuLV Gag in vitro. A GST fusion protein containing
Nuc(212), or GST protein alone, was expressed in bacteria,
extracted, and incubated with lysates of Mo-MuLV-infected
NIH 3T3 cells. The GST and GST-Nuc(212) proteins were then recovered by
binding to glutathione beads. The beads were washed, and the bound
proteins were eluted and analyzed by SDS-gel electrophoresis followed
by Western blotting using polyclonal anti-Gag antisera (Fig.
1). Analysis of the initial
Mo-MuLV-infected NIH 3T3 lysates revealed the presence of the
full-length Gag precursor, Pr65gag, and the
mature CA domain, p30. The GST-Nuc(212) fusion protein efficiently
bound the full-length Gag protein but not CA. In contrast, beads
containing the GST protein alone did not bind the full-length Gag from
the same lysate. These data demonstrate that Nuc(212) can specifically
bind to the full-length Mo-MuLV Gag protein in vitro.
|
Incorporation of Nuc(212) into Mo-MuLV virions.
To investigate
whether Nuc(212) can interact with Mo-MuLV Gag in vivo, we tested for
the incorporation of Nuc(212) into virion particles. COS-7 cells were
transfected with DNAs containing the complete Mo-MuLV genome together
with DNA encoding the Nuc(212) fragment tagged with an
influenza virus HA epitope. Plasmid DNA encoding an irrelevant
HA-tagged protein (annexin II light chain; hereafter called HA-p11) was
used as a negative control. Virions were purified from the culture
supernatants of the transfected cells by sucrose step gradients, and
virion proteins recovered in the pellets were analyzed by gel
electrophoresis followed by Western blotting (Fig.
2A). Probing the
membrane with monoclonal anti-HA antibody revealed that the HA-Nuc(212)
protein was present at high levels in the virions isolated from
cultures expressing both Mo-MuLV and HA-Nuc(212) protein. No
HA-Nuc(212) protein was detected in virion preparations from cultures
that separately expressed HA-Nuc(212) or Mo-MuLV alone, nor was it
detected if the supernatants from the singly transfected cells were
mixed before the virion purification step. Coexpression of Mo-MuLV with HA-p11 did not result in the recovery of HA-p11 in the virion pellet.
These data indicate that Nuc(212) interacts with Mo-MuLV in vivo and is
associated with the virions.
|
Nuc(212) is incorporated inside Mo-MuLV virions.
HA-Nuc(212)
might in principle copurify with Mo-MuLV particles because of an
association with membrane vesicles with a density similar to the
density of the virions (50) or because it can bind to the
outer surface of the budding virions. Cellular proteins associated with
vesicles, however, are sensitive to digestion by subtilisin, while
proteins in the virion core are protected from digestion by the
virion envelope (50). To test whether Nuc(212) was
localized inside the viral envelope, virions were purified by sucrose
step gradients from supernatants of COS-7 cells that coexpressed
Mo-MuLV and HA-Nuc(212) and digested with various concentrations of
subtilisin (50). After digestion, the particles were
purified through a 25% sucrose cushion, and proteins in the
pellets were separated by SDS-gel electrophoresis and detected by
Western blotting. The envelope protein on the virion surface was
degraded by treatment of the virions with low levels of protease, but
the internal Gag protein and the HA-Nuc(212) protein were protected
from digestion even at very high levels of protease (Fig.
3A). The virion-associated Gag and
HA-Nuc(212) proteins were digested by low levels of protease,
however, if the treatments were performed in the presence of detergent
to disrupt the virion membrane (Fig. 3B). These experiments strongly suggest that the HA-Nuc(212) is incorporated inside the virions.
|
Nuc(212) incorporation into virions requires the NC domain.
The incorporation of Nuc(212) into virions might be mediated by
nonspecific interactions with the membrane, or even by the flow of
protein by mass action into assembling particles, or could result from
direct binding to Gag. To determine whether Nuc(212) incorporation
required a specific interaction with the Gag NC domain, we tested both
a modified Mo-MuLV Gag lacking its NC domain and the HIV-1 Gag for the
ability to incorporate Nuc(212). Deletion of NC from Mo-MuLV Gag causes
a drastic reduction in the yield of virions, precluding a direct test
of a mutant Gag simply lacking NC. However, Zhang et al. generated an
assembly-competent variant of the Mo-MuLV Gag (MoZipWT) in which the NC
domain was replaced by a foreign protein, the BZip domain from human
CREB (77). The substituted region of the resulting
construct, pXM-MoZipWT, replaces the assembly function of the NC domain
to allow the formation of high levels of immature virion particles.
COS-7 cells were transfected with DNAs expressing MoZipWT and
HA-Nuc(212), and virions were recovered on sucrose step gradients as
before. Western blot analysis showed that although substantial levels
of particles were produced, no HA-Nuc(212) associated with these
particles was detected (Fig.
4A). Thus, the
incorporation of Nuc(212) into Mo-MuLV virions required the presence of
the NC domain.
|
) and a variant with a deletion affecting
RT (Mo-MuLV
RT) were able to induce high levels of virions;
when coexpressed with HA-Nuc(212), the resulting virions
were found to contain high levels of the tagged protein, similar
to the levels in wild-type virions (Fig. 4B and C). Thus, Gag
processing and an intact Gag-Pol protein are not required for
incorporation of Nuc(212). Thus, the failure of MoZipWT to incorporate
Nuc(212) must be attributed to its lack of an NC domain.
The initial tests for interaction of Nuc(212) with retroviral Gags in
yeast indicated only a very weak interaction with the HIV-1 Gag (Table
1). To test for the incorporation of Nuc(212) into virions
assembled by the HIV-1 Gag, COS-7 cells were transfected with DNAs
containing the HIV-1 provirus and DNA encoding Nuc(212), and virions
were collected and analyzed as before. Particles assembled by HIV-1 Gag
did not incorporate detectable HA-Nuc(212) but did incorporate
HA-tagged cyclophilin A, known to be packaged into HIV-1 virions (Fig.
4D). Examination of very high amounts of HIV-1 particles, encoded by a
different construct expressing high levels of HIV Gag, similarly failed
to detect any incorporated HA-Nuc(212) protein (data not shown).
Estimates from these blots suggest that there was at least 30-fold less
incorporation of HA-Nuc(212) than HA-cyclophilin A into the HIV
virions. As before, HA-Nuc(212) could not be detected in mock virion
preparations from supernatants of control cultures that separately
expressed either HA-Nuc(212), Mo-MuLV, MoZipWT, or HIV alone. These
data strongly suggest that HA-Nuc(212) protein is specifically
incorporated into Mo-MuLV particles, and not generally assembled into
budding viruses, and that this incorporation is dependent not on the
presence of Gag-Pol protein or on Gag processing but rather on the
presence of the Mo-MuLV NC domain.
Overexpression of Nuc(212), but not full-length nucleolin, inhibits retroviral infectivity. The interaction of Nuc(212) with Mo-MuLV Gag in vivo could have various consequences; very high-level expression of Nuc(212) might sequester Gag, block Gag-Gag interactions, or otherwise interfere with normal virion assembly. To test this possibility, we developed a quantitative assay which measures the effect of high-level expression of a candidate inhibitory gene on the ability of a producer cell line to release transducing virus. Phoenix cells, which constitutively express the Mo-MuLV Gag, Pol, and Env proteins, were cotransfected with a retroviral vector DNA transducing the GFP marker and a DNA encoding a potential inhibitor. The transfected cells could be analyzed by flow cytometry to determine the number of cells transfected and the level of expression of the GFP marker. The virus produced by these cells could then be collected, and the yield of infectious virus could be determined by infecting fresh NIH 3T3 cells and analyzing these recipients for the GFP marker by flow cytometry. To achieve high-level expression of the inhibitors, the DNAs encoding these products contained the SV40 origin of replication and thus would be amplified to high copy number by the T antigen present in the Phoenix cells.
Transfection of the Phoenix cells with the GFP vector and various test DNAs showed efficient expression of the GFP marker and no inhibition of expression in the transfected cells by most of the DNAs (data not shown). Expression of HA-Nuc(212), however, caused a drastic reduction in the production of transducing virus. In three experiments, coexpression of the HA-Nuc(212) caused an average 25-fold reduction in the infectivity of the retroviral vector compared to the control HA-p11 protein (Fig. 5A). Coexpression of a full-length nucleolin carrying a Myc epitope tag at the C terminus (nucleolin-Myc) did not significantly reduce the vector titer. To test whether the inhibition was dose dependent, various ratios of the DNA encoding HA-Nuc(212) to the vector expressing HA-p11 were used; the results showed a dose-dependent decrease of the titer of the retroviral vector by increasing levels of HA-Nuc(212) (Fig. 5B). The nucleolin-Myc construct did not show a similar inhibition (Fig. 5C). These results suggest that the high-level expression of Nuc(212) can virtually abolish release of infectious virus, without significant effect on the level of marker gene expression in virus-producing cells.
|
High-level expression of Nuc(212) inhibits Mo-MuLV virion
release.
The inhibition of release of infectious GFP virus
mediated by Nuc(212) could be attributed either to a reduction in the
infectivity of the released virus or to a reduction in the actual
number of particles released by the cells. To determine which was the
case, we tested whether the expression of HA-Nuc(212) could block the production of virion particles expressed from a wild-type Mo-MuLV provirus introduced along with the expression plasmid. 293T cells were
cotransfected with Mo-MuLV DNA and candidate inhibitor constructs, and
the culture supernatants were assayed for RT activity as a measure of
virion particle release. The coexpression of HA-Nuc(212) almost
completely abolished the release of RT, whereas the control protein
HA-p11 had no such effect (Fig. 6A). The
full-length nucleolin-Myc had no inhibitory effect.
|
|
Isolation of a Mo-MuLV Gag mutant with a single point mutation
unable to interact with Nuc(212).
One possible explanation for the
ability of Nuc(212) to inhibit assembly is that it binds to and masks
residues in the Gag protein that are important for assembly. Thus, Gag
mutants that are specifically selected for the loss of the ability to
bind to Nuc(212) might also show defects in assembly. To identify such noninteracting mutants, we used the reverse two-hybrid system (70,
71). A plasmid expressing a Gal4DB fusion to the Mo-MuLV Gag
CA-NC region (pAS1-CANC) was subjected to random mutagenesis by passage
through a mutator E. coli strain. The DNA was then introduced into the reverse two-hybrid yeast strain BY3171 already expressing the Gal4AD-Nuc(212) protein, and Ura
transformants were isolated by selection for growth on 5-FOA. Out of
approximately 104 transformants placed under selection, a
single clone was isolated and retested as a true noninteracting mutant
(see Materials and Methods). Nucleotide sequence analysis of the clone
revealed a single nucleotide substitution changing a single codon and
specifying a change of the penultimate residue of CA, a leucine, to
proline (L477P). The location of this change near the CA-NC boundary is consistent with the contribution of both CA and NC to the interaction with Nuc(212).
|
The L477P mutant of Mo-MuLV fails to assemble virion
particles.
To determine the effects of the L477P mutation on viral
replication and virion assembly, the mutation was transferred to the complete proviral genome. Rat fibroblast cells were transfected with
the mutant DNA, and the spread of virus in the cultures was tested by
assaying for RT activity in the culture medium. Whereas wild-type viral
DNAs induced the appearance of virus and associated RT after 4 days,
the mutant DNA did not result in the formation of detectable virus even
after 1 month of culture (data not shown). These results suggested that
some step in the life cycle was blocked by the mutation. To test for
the ability of the mutant to mediate virion assembly and release
directly, 293T cells were transfected with the L477P mutant or the
wild-type DNA, and the yield of virus released into the culture
supernatant was measured by RT assays. Whereas the wild-type DNA
induced the release of high levels of virion-associated RT, the mutant
DNA produced dramatically reduced RT levels, only slightly above
background (data not shown). Virion particles were isolated from these
culture supernatants, and the levels of CA protein in the virions and
in cell lysates were assessed by Western blotting (Fig.
8). The preparations of wild-type virions showed substantial levels of CA protein, while the L477P mutant preparations contained no detectable CA. In contrast, the intracellular lysates showed higher levels of the Gag proteins in cells expressing the L477P mutant than in those expressing the wild-type. Thus, the
L477P mutant is defective in assembly or release, and the Gag products
accumulate within the producer cell. As for most assembly-defective
mutants, processing of the Gag precursor is impaired in the L477P
mutant.
|
| |
DISCUSSION |
|---|
|
|
|---|
The results presented here demonstrate that the C-terminal portion
of nucleolin interacts specifically with the MuLV Gag protein in a
variety of settings. The interaction could be readily detected in yeast
as binding between two fusion proteins: in vitro, through the binding
of GST-Nuc(212) to the MuLV Gag precursor; and in vivo, through the
NC-dependent incorporation of Nuc(212) into MuLV virion particles. We
suggest that the interaction was mediated by a direct protein-protein
contact rather than by a nucleic acid bridge between the two. Very
small alterations of Gag
a single amino acid substitution
could
abolish the interaction without affecting interactions with other
proteins and without any obvious change in the RNA binding sequences.
Additionally, HIV NC binds RNA but does not bind nucleolin well.
Nevertheless, we note that both Gag and nucleolin are nucleic
acid-binding proteins, and it is plausible that their interaction could
be stimulated or stabilized by bridging nucleic acids.
Nuc(212) interacted with the Gags from many, though not all, retroviruses. The strongest signals were obtained with the MuLVs, while only very weak signals were observed with MPMV and HIV-1. The broad interactions with many Gags presumably reflected a conserved structure of the NC domain, the major site of interaction, among many but not all retroviruses. A surprising consequence of this interaction is the incorporation of Nuc(212) into the virion particle. This incorporation required the presence of the NC domain, and moreover of an NC from a virus that could interact with Nuc(212). Thus, a variant virus in which the NC domain was replaced by a foreign protein did not incorporate Nuc(212), nor could HIV-1 Gag mediate detectable incorporation of the protein. These results correlate completely with the binding seen in yeast and suggest that a direct binding to Gag is required for incorporation. However, it should be noted that the binding of proteins to Gag was not sufficient to mediate the similar incorporation of all such proteins; GIP2, another Gag-interacting protein, bound to the same region of Gag but was not detectably incorporated. The incorporation of Nuc(212) was seen in cells overexpressing an epitope-tagged C-terminal portion of nucleolin, and it remains unclear whether this reflects a role for the endogenous nucleolin in the assembly process (see below). At a minimum, the incorporation of Nuc(212) is strong evidence for its binding to Gag in vivo. We are currently investigating whether Nuc(212) can be used as a targeting domain to direct the efficient encapsidation of fusions to heterologous proteins.
The inhibition of virion release by Nuc(212) was the most striking effect of its high-level overexpression in virus-infected cells. The inhibition was strongly dose dependent; at low levels of expression, there was no effect on virion production, and the only consequence was the incorporation of Nuc(212) into virions. But if the levels of Nuc(212) were very high, virtually all virion release could be blocked. This inhibition was extremely potent; of many Gag-interacting proteins that we have tested, Nuc(212) caused by far the most significant block to virus production. The inhibition was manifested by strong decreases in the release of virus titer, virion-associated RT, and virion proteins, suggesting a block to virion release per se rather than merely an effect on virus infectivity. There are several possible mechanisms by which Nuc(212) could inhibit assembly. Because nucleolin is involved in several steps of ribosome biogenesis, overexpression of a truncated form of nucleolin might be supposed to interfere with general translation, which could lead to reduced amounts of released virus. However, while overexpression of Nuc(212) reduced Gag levels in the supernatants, it did not significantly affect the levels of coexpressed luciferase activity, strongly suggesting that the inhibition of virus release is not the result of a general toxic effect. More importantly, similar levels of Pr65gag were produced in cells overexpressing Nuc(212) and in control cells, arguing that the protein specifically blocks assembly per se. In addition, while Mo-MuLV release was strongly inhibited, HIV-1 release was only slightly reduced, indicating that a tight interaction with Gag is required.
One likely mechanism by which assembly could be inhibited is that Nuc(212) could bind to and directly prevent the multimerization of the Gag precursors required for virion assembly. In this view, Nuc(212) may serve as an "intracellular antibody." The binding of Nuc(212) to NC could mask either NC-NC or NC-RNA interactions, which are thought to play a role in assembly (11, 13, 15, 65). It might also be that the binding of Nuc(212) disrupts assembly by masking the CA-NC junction. Indeed, the L477P mutation, which is adjacent to this junction, disrupted the binding to Nuc(212) and also dramatically inhibited virion assembly. Thus, the CA-NC boundary is a region required for assembly, and masking it or changing its structure results in a defect in assembly. Supporting this idea is the recent observation that Mo-MuLV Gag proteins can be cross-linked at their C-terminal CA residues to form dimers by a cysteine-specific cross-linking agent (47). In addition, an analogous region in HIV-1 (the C-terminal capsid-p2 domain of Pr55gag) is part of the minimal gag sequences needed for efficient assembly of retrovirus-like particles (2). The reduction in processing of the Gag precursor observed in Nuc(212)-expressing cells is consistent with this model; activation of the viral protease and Gag cleavage depends on normal multimerization of Gag and Gag-Pol proteins associated with assembly (44, 57, 61).
Another possibility is that the Nuc(212) fragment acts as a dominant negative allele that interferes with a positive assembly function of the endogenous wild-type nucleolin during virion assembly. In this case, the wild-type nucleolin would need to bind to Gag to promote its assembly. The NC domain contains the I domain, an important assembly domain for many retroviruses (65), and nucleolin binding may be a part of that domain's function. It has been suggested that a nonspecific interaction of NC with RNA may also be required for assembly (11, 13, 15). Nucleolin could possibly be involved in promoting the binding of RNA to Gag during this process. Indeed, nucleolin has been suggested to serve as an RNA chaperone, capable of delivering RNA to assembling ribosomal proteins and assisting in their folding and binding (for a recent review, see reference 29). The assembly of a retrovirus particle has many similarities to the assembly of a ribosome, and it is thus possible that nucleolin helps deliver viral RNA to the assembling Gag proteins. Interestingly, nucleolin has been shown to associate with the capsid protein of adeno-associated virus type 2 and has been proposed to have a role in virion assembly in this system (54).
If nucleolin is important for Mo-MuLV assembly, then Gag mutants that cannot bind should show defects for virion assembly. The L477P substitution is one such mutant. This single substitution strongly blocked the interaction with Nuc(212), with minimal effects on its ability to interact with other proteins; concomitantly, the mutation caused a nearly complete block to virus production and the accumulation of Gag in the cell. This finding does not prove but is consistent with the possibility that an interaction with nucleolin plays a positive role in virion production. If so, a direct binding should be demonstrated between Mo-MuLV Gag protein and endogenous nucleolin or its cleavage products (24, 64), which has been reported in different contexts and various intracellular locations (12, 38, 60, 76). However, our attempts to identify the HA- or Myc-tagged full-length nucleolin in assembled virions or as proteins bound to Mo-MuLV Gag in coimmunoprecipitation experiments have failed (data not shown). The availability of only poor polyclonal antisera against nucleolin and of monoclonal antibodies specific only for epitope tags, which may not be retained on many of nucleolin's cleavage products, have frustrated our efforts to test the binding of such molecules to Gag. We have not been able to obtain any direct evidence of an involvement of nucleolin in Mo-MuLV assembly, and such a physiological role still remains only a possibility.
In summary, we have identified a specific interaction of Nuc(212) with the Mo-MuLV Gag precursor. The binding of Nuc(212) resulted in a strong inhibition of virion assembly or release in vivo. Nuc(212) could serve as a model for other inhibitors of virion assembly, including potentially therapeutic antivirals that would similarly bind to NC or other domains required for assembly. It also raises the possibility that endogenous nucleolin may play a positive role in the assembly of Mo-MuLV particles. Finally, the experiments presented here indicate a critical involvement of the CA-NC boundary in the process of Mo-MuLV assembly. Further experiments should help determine the exact step in virion formation blocked by CA-NC mutations and the fate of mutant Gags that are unable to form particles.
| |
ACKNOWLEDGMENTS |
|---|
We thank Paul Jolicoeur, Rolf Sternglanz, Ed Harlow, Erik Barklis, Jeremy Luban, Gary Nolan, Stephen Elledge, and Manfred Schubert for generously providing various reagents. We also thank Guangxia Gao, Marion Dorsch, and Matthew Evans for helpful discussions and Sharon Boast and Kenia de los Santos for technical assistance.
This work was supported by PHS grant CA 30488 from the National Cancer Institute. E.B. and M.O. are Associates, and S.P.G. is an Investigator, of the Howard Hughes Medical Institute.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Biochemistry and Molecular Biophysics, College of Physicians and Surgeons, Columbia University, New York, NY 10032. Phone: (212) 305-3794. Fax: (212) 305-8692. E-mail: goff{at}cuccfa.ccc.columbia.edu.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Accola, M. A.,
S. Hoglund, and H. G. Gottlinger.
1998.
A putative alpha-helical structure which overlaps the capsid-p2 boundary in the human immunodeficiency virus type 1 Gag precursor is crucial for viral particle assembly.
J. Virol.
72:2072-2078 |
| 2. |
Accola, M. A.,
B. Strack, and H. G. Gottlinger.
2000.
Efficient particle production by minimal Gag constructs which retain the carboxy-terminal domain of human immunodeficiency virus type 1 capsid-p2 and a late assembly domain.
J. Virol.
74:5395-5402 |
| 3. | Alin, K., and S. P. Goff. 1996. Amino acid substitutions in the CA protein of Moloney murine leukemia virus that block early events in infection. Virology 222:339-351[CrossRef][Medline]. |
| 4. | Alin, K., and S. P. Goff. 1996. Mutational analysis of interactions between the Gag precursor proteins of murine leukemia viruses. Virology 216:418-424[CrossRef][Medline]. |
| 5. |
Bacharach, E., and S. P. Goff.
1998.
Binding of the human immunodeficiency virus type 1 Gag protein to the viral RNA encapsidation signal in the yeast three-hybrid system.
J. Virol.
72:6944-6949 |
| 6. | Bartel, P. L., and S. Fields (ed.). 1997. The yeast two-hybrid system. Oxford University Press, Oxford, United Kingdom. |
| 7. |
Boone, L. R.,
F. E. Myer,
D. M. Yang,
C. Y. Ou,
C. K. Koh,
L. E. Roberson,
R. W. Tennant, and W. K. Yang.
1983.
Reversal of Fv-1 host range by in vitro restriction endonuclease fragment exchange between molecular clones of N-tropic and B-tropic murine leukemia virus genomes.
J. Virol.
48:110-119 |
| 8. | Bourbon, H. M., B. Lapeyre, and F. Amalric. 1988. Structure of the mouse nucleolin gene. The complete sequence reveals that each RNA binding domain is encoded by two independent exons. J. Mol. Biol. 200:627-638[CrossRef][Medline]. |
| 9. | Bouvet, P., C. Jain, J. G. Belasco, F. Amalric, and M. Erard. 1997. RNA recognition by the joint action of two nucleolin RNA-binding domains: genetic analysis and structural modeling. EMBO J. 16:5235-5246[CrossRef][Medline]. |
| 10. |
Bugler, B.,
H. Bourbon,
B. Lapeyre,
M. O. Wallace,
J. H. Chang,
F. Amalric, and M. O. Olson.
1987.
RNA binding fragments from nucleolin contain the ribonucleoprotein consensus sequence.
J. Biol. Chem.
262:10922-10925 |
| 11. |
Burniston, M. T.,
A. Cimarelli,
J. Colgan,
S. P. Curtis, and J. Luban.
1999.
Human immunodeficiency virus type 1 Gag polyprotein multimerization requires the nucleocapsid domain and RNA and is promoted by the capsid-dimer interface and the basic region of matrix protein.
J. Virol.
73:8527-8540 |
| 12. |
Callebaut, C.,
J. Blanco,
N. Benkirane,
B. Krust,
E. Jacotot,
G. Guichard,
N. Seddiki,
J. Svab,
E. Dam,
S. Muller,
J. P. Briand, and A. G. Hovanessian.
1998.
Identification of V3 loop-binding proteins as potential receptors implicated in the binding of HIV particles to CD4(+) cells.
J. Biol. Chem.
273:21988-1997 |
| 13. |
Campbell, S., and A. Rein.
1999.
In vitro assembly properties of human immunodeficiency virus type 1 Gag protein lacking the p6 domain.
J. Virol.
73:2270-2279 |
| 14. |
Cimarelli, A., and J. Luban.
1999.
Translation elongation factor 1-alpha interacts specifically with the human immunodeficiency virus type 1 Gag polyprotein.
J. Virol.
73:5388-5401 |
| 15. |
Cimarelli, A.,
S. Sandin,
S. Hoglund, and J. Luban.
2000.
Basic residues in human immunodeficiency virus type 1 nucleocapsid promote virion assembly via interaction with RNA.
J. Virol.
74:3046-3057 |
| 16. | Colicelli, J., and S. P. Goff. 1988. Sequence and spacing requirements of a retrovirus integration site. J. Mol. Biol. 199:47-59[CrossRef][Medline]. |
| 17. |
Crawford, S., and S. P. Goff.
1984.
Mutations in Gag proteins P12 and P15 of Moloney murine leukemia virus block early stages of infection.
J. Virol.
49:909-917 |
| 18. | Creancier, L., H. Prats, C. Zanibellato, F. Amalric, and B. Bugler. 1993. Determination of the functional domains involved in nucleolar targeting of nucleolin. Mol. Biol. Cell 4:1239-1250[Abstract]. |
| 19. | Delchambre, M., D. Gheysen, D. Thines, C. Thiriart, E. Jacobs, E. Verdin, M. Horth, A. Burny, and F. Bex. 1989. The GAG precursor of simian immunodeficiency virus assembles into virus-like particles. EMBO J. 8:2653-2660[Medline]. |
| 20. |
DesGroseillers, L., and P. Jolicoeur.
1983.
Physical mapping of the Fv-1 tropism host range determinant of BALB/c murine leukemia viruses.
J. Virol.
48:685-696 |
| 21. | Dickson, C., R. Eisenman, H. Fan, E. Hunter, and N. Teich. 1984. Protein biosynthesis and assembly, p. 513-648. In R. Weiss, T. Teich, H. Varmus, and J. Coffin (ed.), RNA tumor viruses. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. |
| 22. |
Dorsch, M.,
P. D. Fan,
N. N. Danial,
P. B. Rothman, and S. P. Goff.
1997.
The thrombopoietin receptor can mediate proliferation without activation of the Jak-STAT pathway.
J. Exp. Med.
186:1947-1955 |
| 23. |
Durfee, T.,
K. Becherer,
P. L. Chen,
S. H. Yeh,
Y. Yang,
A. E. Kilburn,
W. H. Lee, and S. J. Elledge.
1993.
The retinoblastoma protein associates with the protein phosphatase type 1 catalytic subunit.
Genes Dev.
7:555-569 |
| 24. | Fang, S. H., and N. H. Yeh. 1993. The self-cleaving activity of nucleolin determines its molecular dynamics in relation to cell proliferation. Exp. Cell Res. 208:48-53[CrossRef][Medline]. |
| 25. | Franke, E. K., H. E. Yuan, and J. Luban. 1994. Specific incorporation of cyclophilin A into HIV-1 virions. Nature 372:359-362[CrossRef][Medline]. |
| 26. |
Gao, G., and S. P. Goff.
1998.
Replication defect of Moloney murine leukemia virus with a mutant reverse transcriptase that can incorporate ribonucleotides and deoxyribonucleotides.
J. Virol.
72:5905-5911 |
| 27. |
Ghisolfi, L.,
G. Joseph,
F. Amalric, and M. Erard.
1992.
The glycine-rich domain of nucleolin has an unusual supersecondary structure responsible for its RNA-helix-destabilizing properties.
J. Biol. Chem.
267:2955-2959 |
| 28. | Ghisolfi, L., A. Kharrat, G. Joseph, F. Amalric, and M. Erard. 1992. Concerted activities of the RNA recognition and the glycine-rich C-terminal domains of nucleolin are required for efficient complex formation with pre-ribosomal RNA. Eur. J. Biochem. 209:541-548[Medline]. |
| 29. | Ginisty, H., H. Sicard, B. Roger, and P. Bouvet. 1999. Structure and functions of nucleolin. J. Cell Sci. 112:761-772[Abstract]. |
| 30. | Goff, S. P. 1996. Operating under a Gag order: a block against incoming virus by the Fv1 gene. Cell 86:691-693[CrossRef][Medline]. |
| 31. | Gorelick, R. J., D. J. Chabot, D. E. Ott, T. D. Gagliardi, A. Rein, L. E. Henderson, and L. O. Arthur. 1996. Genetic analysis of the zinc finger in the Moloney murine leukemia virus nucleocapsid domain: replacement of zinc-coordinating residues with other zinc-coordinating residues yields noninfectious particles containing genomic RNA. J. Virol. 70:2593-2597[Abstract]. |
| 32. |
Gorelick, R. J.,
L. E. Henderson,
J. P. Hanser, and A. Rein.
1988.
Point mutants of Moloney murine leukemia virus that fail to package viral RNA: evidence for specific RNA recognition by a "zinc finger-like" protein sequence.
Proc. Natl. Acad. Sci. USA
85:8420-8424 |
| 33. | Granowitz, C., and S. P. Goff. 1994. Substitution mutations affecting a small region of the Moloney murine leukemia virus MA gag protein block assembly and release of virion particles. Virology 205:336-344[CrossRef][Medline]. |
| 34. |
Grignani, F.,
T. Kinsella,
A. Mencarelli,
M. Valtieri,
D. Riganelli,
L. Lanfrancone,
C. Peschle,
G. P. Nolan, and P. G. Pelicci.
1998.
High-efficiency gene transfer and selection of human hematopoietic progenitor cells with a hybrid EBV/retroviral vector expressing the green fluorescence protein.
Cancer Res.
58:14-19 |
| 35. | Hanes, S. D., and R. Brent. 1989. DNA specificity of the bicoid activator protein is determined by homeodomain recognition helix residue 9. Cell 57:1275-1283[CrossRef][Medline]. |
| 36. | Heine, M. A., M. L. Rankin, and P. J. DiMario. 1993. The Gly/Arg-rich (GAR) domain of Xenopus nucleolin facilitates in vitro nucleic acid binding and in vivo nucleolar localization. Mol. Biol. Cell 4:1189-1204[Abstract]. |
| 37. | Hsu, H. W., P. Schwartzberg, and S. P. Goff. 1985. Point mutations in the P30 domain of the gag gene of Moloney murine leukemia virus. Virology 142:211-214[CrossRef][Medline]. |
| 38. | Issinger, O. G., T. Martin, W. W. Richter, M. Olson, and H. Fujiki. 1988. Hyperphosphorylation of N-60, a protein structurally and immunologically related to nucleolin after tumour-promoter treatment. EMBO J. 7:1621-1626[Medline]. |
| 39. |
Kalpana, G. V., and S. P. Goff.
1993.
Genetic analysis of homomeric interactions of human immunodeficiency virus type 1 integrase using the yeast two-hybrid system.
Proc. Natl. Acad. Sci. USA
90:10593-10597 |
| 40. |
Kim, W.,
Y. Tang,
Y. Okada,
T. A. Torrey,
S. K. Chattopadhyay,
M. Pfleiderer,
F. G. Falkner,
F. Dorner,
W. Choi,
N. Hirokawa, and H. C. Morse, III.
1998.
Binding of murine leukemia virus Gag polyproteins to KIF4, a microtubule-based motor protein.
J. Virol.
72:6898-6901 |
| 41. |
Lama, J., and D. Trono.
1998.
Human immunodeficiency virus type 1 matrix protein interacts with cellular protein HO3.
J. Virol.
72:1671-1676 |
| 42. | Li, X., B. Yuan, and S. P. Goff. 1997. Genetic analysis of interactions between Gag proteins of Rous sarcoma virus. J. Virol. 71:5624-5630[Abstract]. |
| 43. | Lischwe, M. A., R. G. Cook, Y. S. Ahn, L. C. Yeoman, and H. Busch. 1985. Clustering of glycine and NG,NG-dimethylarginine in nucleolar protein C23. Biochemistry 24:6025-6028[CrossRef][Medline]. |
| 44. | Luban, J., K. L. Bossolt, E. K. Franke, G. V. Kalpana, and S. P. Goff. 1993. Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B. Cell 73:1067-1078[CrossRef][Medline]. |
| 45. | Ma, J., and M. Ptashne. 1987. A new class of yeast transcriptional activators. Cell 51:113-119[CrossRef][Medline]. |
| 46. |
Maldarelli, F.,
M. A. Martin, and K. Strebel.
1991.
Identification of posttranscriptionally active inhibitory sequences in human immunodeficiency virus type 1 RNA: novel level of gene regulation.
J. Virol.
65:5732-5743 |
| 47. | McDermott, J., S. Karanjia, Z. Love, and E. Barklis. 2000. Crosslink analysis of N-terminal, C-terminal, and N/B determining regions of the Moloney murine leukemia virus capsid protein. Virology 269:190-200[CrossRef][Medline]. |
| 48. |
Meric, C., and S. P. Goff.
1989.
Characterization of Moloney murine leukemia virus mutants with single-amino-acid substitutions in the Cys-His box of the nucleocapsid protein.
J. Virol.
63:1558-1568 |
| 49. | Olson, M. O., M. N. Kirstein, and M. O. Wallace. 1990. Limited proteolysis as a probe of the conformation and nucleic acid binding regions of nucleolin. Biochemistry 29:5682-5686[CrossRef][Medline]. |
| 50. | Ott, D. E., L. V. Coren, B. P. Kane, L. K. Busch, D. G. Johnson, R. C. Sowder II, E. N. Chertova, L. O. Arthur, and L. E. Henderson. 1996. Cytoskeletal proteins inside human immunodeficiency virus type 1 virions. J. Virol. 70:7734-7743[Abstract]. |
| 51. |
Ou, C. Y.,
L. R. Boone,
C. K. Koh,
R. W. Tennant, and W. K. Yang.
1983.
Nucleotide sequences of gag-pol regions that determine the Fv-1 host range property of BALB/c N-tropic and B-tropic murine leukemia viruses.
J. Virol.
48:779-784 |
| 52. |
Pear, W. S.,
G. P. Nolan,
M. L. Scott, and D. Baltimore.
1993.
Production of high-titer helper-free retroviruses by transient transfection.
Proc. Natl. Acad. Sci. USA
90:8392-8396 |
| 53. | Pinter, A., W. J. Honnen, J. S. Tung, P. V. O'Donnell, and U. Hammerling. 1982. Structural domains of endogenous murine leukemia virus gp70s containing specific antigenic determinants defined by monoclonal antibodies. Virology 116:499-516[CrossRef][Medline]. |
| 54. | Qiu, J., and K. E. Brown. 1999. A 110-kDa nuclear shuttle protein, nucleolin, specifically binds to adeno-associated virus type 2 (AAV-2) capsid. Virology 257:373-382[CrossRef][Medline]. |
| 55. | Reicin, A. S., A. Ohagen, L. Yin, S. Hoglund, and S. P. Goff. 1996. The role of Gag in human immunodeficiency virus type 1 virion morphogenesis and early steps of the viral life cycle. J. Virol. 70:8645-8652[Abstract]. |
| 56. |
Rein, A.,
D. P. Harvin,
J. Mirro,
S. M. Ernst, and R. J. Gorelick.
1994.
Evidence that a central domain of nucleocapsid protein is required for RNA packaging in murine leukemia virus.
J. Virol.
68:6124-6129 |
| 57. |
Rein, A.,
M. R. McClure,
N. R. Rice,
R. B. Luftig, and A. M. Schultz.
1986.
Myristylation site in Pr65gag is essential for virus particle formation by Moloney murine leukemia virus.
Proc. Natl. Acad. Sci. USA
83:7246-7250 |
| 58. |
Reiser, J.,
G. Harmison,
S. Kluepfel-Stahl,
R. O. Brady,
S. Karlsson, and M. Schubert.
1996.
Transduction of nondividing cells using pseudotyped defective high-titer HIV type 1 particles.
Proc. Natl. Acad. Sci. USA
93:15266-15271 |
| 59. | Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. |
| 60. | Sapp, M., A. Richter, K. Weisshart, M. Caizergues-Ferrer, F. Amalric, M. O. Wallace, M. N. Kirstein, and M. O. Olson. 1989. Characterization of a 48-kDa nucleic-acid-binding fragment of nucleolin. Eur. J. Biochem. 179:541-548[Medline]. |
| 61. |
Schwartzberg, P.,
J. Colicelli,
M. L. Gordon, and S. P. Goff.
1984.
Mutations in the gag gene of Moloney murine leukemia virus: effects on production of virions and reverse transcriptase.
J. Virol.
49:918-924 |
| 62. | Shields, A., W. N. Witte, E. Rothenberg, and D. Baltimore. 1978. High frequency of aberrant expression of Moloney murine leukemia virus in clonal infections. Cell 14:601-609[CrossRef][Medline]. |
| 63. | Shioda, T., and H. Shibuta. 1990. Production of human immunodeficiency virus (HIV)-like particles from cells infected with recombinant vaccinia viruses carrying the gag gene of HIV. Virology 175:139-148[CrossRef][Medline]. |
| 64. | Suzuki, T., N. Suzuki, and T. Hosoya. 1993. Limited proteolysis of rat liver nucleolin by endogenous proteases: effects of polyamines and histones. Biochem. J. 289:109-115. |
| 65. | Swanstrom, R., and J. W. Wills. 1997. Synthesis, assembly, and processing of viral proteins, p. 263-334. In J. M. Coffin, S. H. Hughes, and H. E. Varmus (ed.), Retroviruses. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. |
| 66. | Tanaka, M., and W. Herr. 1990. Differential transcriptional activation by Oct-1 and Oct-2: interdependent activation domains induce Oct-2 phosphorylation. Cell 60:375-386[CrossRef][Medline]. |
| 67. |
Tang, Y.,
U. Winkler,
E. O. Freed,
T. A. Torrey,
W. Kim,
H. Li,
S. P. Goff, and H. C. Morse, III.
1999.
Cellular motor protein KIF-4 associates with retroviral Gag.
J. Virol.
73:10508-10513 |
| 68. | Telesnitsky, A., S. Blain, and S. P. Goff. 1995. Assays for retroviral reverse transcriptase. Methods Enzymol. 262:347-362[Medline]. |
| 69. | Tuteja, N., N. W. Huang, D. Skopac, R. Tuteja, S. Hrvatic, J. Zhang, S. Pongor, G. Joseph, C. Faucher, F. Amalric, et al. 1995. Human DNA helicase IV is nucleolin, an RNA helicase modulated by phosphorylation. Gene 160:143-148[CrossRef][Medline]. |
| 70. |
Vidal, M.,
R. K. Brachmann,
A. Fattaey,
E. Harlow, and J. D. Boeke.
1996.
Reverse two-hybrid and one-hybrid systems to detect dissociation of protein-protein and DNA-protein interactions.
Proc. Natl. Acad. Sci. USA
93:10315-10320 |
| 71. |
Vidal, M.,
P. Braun,
E. Chen,
J. D. Boeke, and E. Harlow.
1996.
Genetic characterization of a mammalian protein-protein interaction domain by using a yeast reverse two-hybrid system.
Proc. Natl. Acad. Sci. USA
93:10321-10326 |
| 72. | Wills, J. W., and R. C. Craven. 1991. Form, function, and use of retroviral gag proteins. AIDS 5:639-654[Medline]. |
| 73. |
Yu, X.,
Q. C. Yu,
T. H. Lee, and M. Essex.
1992.
The C terminus of human immunodeficiency virus type 1 matrix protein is involved in early steps of the virus life cycle.
J. Virol.
66:5667-5670 |
| 74. |
Yuan, B.,
S. Campbell,
E. Bacharach,
A. Rein, and S. P. Goff.
2000.
Infectivity of Moloney murine leukemia virus defective in late assembly events is restored by late assembly domains of other retroviruses.
J. Virol.
74:7250-7260 |
| 75. | Yuan, B., X. Li, and S. P. Goff. 1999. Mutations altering the Moloney murine leukemia virus p12 Gag protein affect virion production and early events of the virus life cycle. EMBO J. 18:4700-4710[CrossRef][Medline]. |
| 76. |
Zaidi, S. H., and J. S. Malter.
1995.
Nucleolin and heterogeneous nuclear ribonucleoprotein C proteins specifically interact with the 3'-untranslated region of amyloid protein precursor mRNA.
J. Biol. Chem.
270:17292-17298 |
| 77. |
Zhang, Y.,
H. Qian,
Z. Love, and E. Barklis.
1998.
Analysis of the assembly function of the human immunodeficiency virus type 1 Gag protein nucleocapsid domain.
J. Virol.
72:1782-789 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»